Skip to main content

Table 3 Multivariate analysis of primary and secondary outcomes in the HOMA-IR groups

From: Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study

 

Model 1

 

Model 2

 
 

Odds ratio (95% CI)

p-value

Odds ratio (95% CI)

p-value

New onset DM

    

 HbA1c (%)

28.1(16.9–46.5)

< 0.001

28.9 (16.9–49.8)

< 0.001

 Low HOMA-IR

Reference

 

Reference

 

 Moderate HOMA-IR

0.78 (0.49–1.26)

0.31

0.91 (0.55–1.51)

0.72

 High HOMA-IR

1.42 (0.95–2.14)

0.09

1.86 (1.17–2.96)

0.01

Chronic kidney disease

    

 HbA1c (%)

1.15 (0.85–1.55)

0.36

1.10 (0.80–1.52)

0.56

 Moderate HOMA-IR

1.07(0.81–1.40)

0.65

1.01 (0.75–1.36)

0.96

 High HOMA-IR

1.42 (1.10–1.84)

0.01

1.49 (1.12–1.98)

0.01

Macrovascular event

    

 HbA1c (%)

1.43 (0.81–2.54)

0.22

1.31 (0.71–2.44)

0.39

 Moderate HOMA-IR

0.67 (0.41–1.11)

0.12

0.64 (0.38–1.09)

0.11

 High HOMA-IR

0.84 (0.52–1.34)

0.46

0.91 (0.53–1.56)

0.74

  1. Model 1, adjusted for HbA1c, age, sex, current smoking, hypertension, dyslipidaemia, myocardial infarction, heart failure, chronic kidney disease; Model 2, adjusted for factors in model 1 as well as high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, C-reactive protein, homeostasis model assessment of β-cell function, glomerular filtration rate, and body mass index
Back to article page

Clinical Diabetes and Endocrinology

ISSN: 2055-8260

Contact us